Fundamental Analysis of ONCONETIX INC(NASDAQ:ONCO) stock

Fundamental Rating

Taking everything into account, ONCO scores 0 out of 10 in our fundamental rating. ONCO was compared to 564 industry peers in the Biotechnology industry. ONCO may be in some trouble as it scores bad on both profitability and health. ONCO is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

ONCO had negative earnings in the past year.

ONCO had a negative operating cash flow in the past year.

ONCO had negative earnings in each of the past 5 years.

ONCO had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ONCO has a worse Return On Assets (-83.34%) than 70.56% of its industry peers.

The Return On Equity of ONCO (-152.17%) is worse than 64.81% of its industry peers.

		Industry Rank	Sector Rank
ROA	-83.34%
ROE	-152.17%
ROIC	N/A

ROA(3y)-75.1%

ROA(5y)-57.66%

ROE(3y)-134.27%

ROE(5y)-93.36%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ONCO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ONCO does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ONCO has less shares outstanding

The debt/assets ratio for ONCO is higher compared to a year ago.

2.2 Solvency

ONCO has an Altman-Z score of -2.95. This is a bad value and indicates that ONCO is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of ONCO (-2.95) is comparable to the rest of the industry.

ONCO has a Debt/Equity ratio of 0.29. This is a healthy value indicating a solid balance between debt and equity.

ONCO has a worse Debt to Equity ratio (0.29) than 70.20% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.29
Debt/FCF	N/A
Altman-Z	-2.95

ROIC/WACCN/A

WACC9.81%

2.3 Liquidity

A Current Ratio of 0.06 indicates that ONCO may have some problems paying its short term obligations.

With a Current ratio value of 0.06, ONCO is not doing good in the industry: 99.28% of the companies in the same industry are doing better.

A Quick Ratio of 0.05 indicates that ONCO may have some problems paying its short term obligations.

ONCO has a Quick ratio of 0.05. This is amonst the worse of the industry: ONCO underperforms 99.28% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.06
Quick Ratio	0.05

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ONCO have decreased strongly by -8438.23% in the last year.

EPS 1Y (TTM)-8438.23%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-845.26%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

ONCO is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -14.13% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-11.84%

EPS Next 2Y-14.13%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ONCO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ONCO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ONCO's earnings are expected to decrease with -14.13% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-14.13%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ONCO!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ONCONETIX INC

NASDAQ:ONCO (1/3/2025, 8:00:02 PM)

After market: 0.815 +0.01 (+0.65%)

0.8097

+0.16 (+24.36%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-12 2024-05-12

Earnings (Next)N/A N/A

Inst Owners1.26%

Inst Owner ChangeN/A

Ins Owners11.45%

Ins Owner Change25.63%

Market Cap6.71M

Analysts43.33

Price TargetN/A

Short Float %1.64%

Short Ratio0.15

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	3.59
P/FCF	N/A
P/OCF	N/A
P/B	0.2
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-95.63

EYN/A

EPS(NY)-1.01

Fwd EYN/A

FCF(TTM)-1.68

FCFYN/A

OCF(TTM)-1.68

OCFYN/A

SpS0.23

BVpS4.09

TBVpS-3.18

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-83.34%
ROE	-152.17%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-75.1%

ROA(5y)-57.66%

ROE(3y)-134.27%

ROE(5y)-93.36%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0.03

Health

		Industry Rank	Sector Rank
Debt/Equity	0.29
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	4.48%
Cap/Sales	1.57%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.06
Quick Ratio	0.05
Altman-Z	-2.95

F-Score3

WACC9.81%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-8438.23%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-845.26%

EPS Next Y-11.84%

EPS Next 2Y-14.13%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-14.41%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-111.53%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-111.4%

OCF growth 3YN/A

OCF growth 5YN/A

ONCONETIX INC (ONCO)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens